These analysts have a neutral stance on Intuitive Surgical despite its high-margin business model and the unique nature of da Vinci robotic surgery as they remain skeptical about a sustained recovery by capital equipment manufacturers, in the US and Europe, which influences system sales and initial stocking orders, as well as instrument inventories. The analysts believe that the company's growth remains contingent on further recovery in hospital capital spending budgets and the continued adoption of robotic procedures. Further, certain procedures, such as those related to prostate, appear to have reached a plateau in the US. In the end, the neutral analysts choose to remain on the sidelines as they perceive the valuation of the company to be too high.